Helen Chen

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Journal for ImmunoTherapy of Cancer · 2020 · 262 citations

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy:…

The Lancet Oncology · 2022 · 226 citations